NR4A1 and breast carcinoma: To lend support for this hypothesis, we performed immunohistochemistry staining of PGR and PGR_pS162 in a cohort of 361 breast cancer patients with known hormone-receptor status (PGR +/− and/or ER +/−; Fig. 6e, Supplementary Methods).